Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1422142/000119312518205840/d638665d8k.htm
August 2021
August 2021
August 2021
August 2021
July 2021
June 2021
May 2021
May 2021
April 2021
March 2021
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1422142/000119312518205840/d638665d8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aerpio Pharmaceuticals, Inc..
Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ARPOEvents:
CIK: 1422142
Form Type: 8-K Corporate News
Accession Number: 0001193125-18-205840
Submitted to the SEC: Wed Jun 27 2018 4:56:05 PM EST
Accepted by the SEC: Wed Jun 27 2018
Period: Tuesday, June 26, 2018
Industry: Pharmaceutical Preparations